RLYB
Rallybio Corp
Next earnings ≈ Aug 12, 2026 · est. from filing cadence
Last earnings +2.2% on 2025-11-06
$16.00
▲ +1.85%$16.00▲ +500.60%
over 1Y
L $2.58EODHDH $16.23
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.8%
1W+1.8%
1M+10.1%
3M+94.6%
YTD+182.8%
1Y+500.6%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Sell
Revenue grew 34.9% YoY; but unprofitable (net margin -1046.4%).
Revenue (FY2025) $858K · FY2025
Rallybio Corp shows $858K in FY2025 revenue (+34.9% YoY), a -1046.4% net margin, and -15.5% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $636K | $858K |
| Gross profit | — | — | — | — | — |
| Operating income | -$45.6M | -$67.9M | -$78.9M | -$60.5M | -$33.1M |
| Net income | -$47.0M | -$66.7M | -$74.6M | -$57.8M | -$8.98M |
| Diluted EPS | -$1.84 | -$2.09 | -$1.84 | -$10.61 | -$1.59 |
| Net margin | — | — | — | -9084.1% | -1046.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$53.3M
EV / EBITDA—
EV / Sales62.1
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-10.6%
FCF yield-35.2%
Quality & risk
ROIC (est.)-45.1%
Free cash flow-$29.8M
Total debt—
Net cash$31.4M
Altman Z-Score4.37 safe
Piotroski F-Score4/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-87.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-05-04). Worth a closer look.
Recent filings
all on EDGAR ↗SCHEDULE 13GFiling2026-06-05open ↗425Filing2026-06-01open ↗8-KPeriod ending 2026-05-312026-06-01open ↗4Period ending 2026-05-182026-05-20open ↗4Period ending 2026-05-132026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗4Period ending 2026-05-112026-05-13open ↗10-QPeriod ending 2026-03-312026-05-13open ↗4Period ending 2026-05-042026-05-06open ↗
Frequently asked
- Is Rallybio Corp (RLYB) a buy?
- RLYB currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 34.9% YoY; but unprofitable (net margin -1046.4%).
- What is Rallybio Corp's quality score?
- RLYB scores 49.11764705882352/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001739410, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 8:39:55 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.